Appointed
Christy J. Oliger
Class III director
NUVL ·
Nuvalent, Inc.
the Board elected Christy J. Oliger as a member of the Board, effective immediately.
NUVL
Nuvalent, Inc.
Saved in this browser
Ready 8-Ks
15
Latest filing
May 07, 2026 23:59 UTC
Top materiality
0.85
Event mix
other_material ×7 · earnings ×3 · leadership ×3
Sentiment
6 pos · 0 neg · 9 neu
Latest earnings
reported 2025-FY
Executive change
recent →
Recent 8-K filings for NUVL
Highest-materiality recent filing
Nuvalent submits NDA for neladalkib in ALK+ NSCLC; zidesamtinib PDUFA Sept 18, 2026
- NDA for neladalkib in TKI pre-treated ALK+ NSCLC submitted; pivotal data at ASCO 2026.
- Zidesamtinib NDA under FDA review; PDUFA target action date September 18, 2026.
-
Nuvalent submits NDA for neladalkib in ALK+ NSCLC; zidesamtinib PDUFA Sept 18, 2026
NDA for neladalkib in TKI pre-treated ALK+ NSCLC submitted; pivotal data at ASCO 2026.
-
Nuvalent submits NDA to FDA for neladalkib in ALK-positive lung cancer
NDA submitted to FDA on April 7, 2026, for neladalkib in TKI pre-treated advanced ALK-positive NSCLC.
-
Nuvalent reports Q4 and FY2025 net loss; zidesamtinib PDUFA set for Sept 18, 2026
Net loss of $118.7M in Q4 2025 and $425.4M for full year 2025.
-
Nuvalent reports $1.4B cash, zidesamtinib PDUFA Sep 18, 2026; pipeline milestones
Preliminary cash, cash equivalents and securities ~$1.4B as of Dec 31, 2025; runway into 2029.
-
Royalty Pharma buys 1.5% royalty on Nuvalent's pipeline for up to $315M
Royalty Pharma acquired a preexisting 1.5% net-sales royalty on neladalkib and zidesamtinib from an undisclosed third party.
-
Nuvalent director Matthew Shair resigns; Ron Squarer elected to board
Matthew Shair, Ph.D., resigned from the Board effective Dec 9, 2025, and not due to any disagreement.
-
Nuvalent prices $500M public offering at $101/share; net proceeds ~$472M
Pricing of 4,950,496 shares at $101.00/share for gross proceeds of ~$500M.
-
Neladalkib achieved 31% ORR (79/253) in TKI pre-treated ALK+ NSCLC; median DOR not reached at 11.3 months follow-up.
-
Nuvalent Q3 net loss $122.4M; completes NDA for zidesamtinib; cash $943M into 2028
Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC.
-
Nuvalent completes NDA submission to FDA for zidesamtinib in ROS1-positive NSCLC
Completed NDA submission to FDA for zidesamtinib.
-
Nuvalent Q2 2025 net loss $99.7M; rolling NDA for zidesamtinib initiated
Net loss $99.7M; R&D $80.9M, G&A $23.7M; cash $1.0B funding into 2028.
-
Nuvalent initiates Phase 3 ALKAZAR trial of neladalkib in ALK-positive NSCLC
First patient dosed in Phase 3 ALKAZAR trial evaluating neladalkib for TKI-naïve advanced ALK-positive NSCLC.
-
Zidesamtinib achieved 44% ORR (51/117) in TKI pre-treated ROS1+ NSCLC; intracranial ORR 48% (27/56) with 20% complete responses.
-
Nuvalent elects Christy Oliger as new board member; 2025 annual meeting results disclosed
Christy J. Oliger elected to Board as Class III director, effective June 18, 2025; appointed to Audit Committee.
-
Director Emily Conley resigns from Nuvalent board effective at 2025 annual meeting
Emily Conley notified Nuvalent of her resignation from the Board and all committees, effective at the 2025 annual meeting.
Executive changes
Departed
Emily Conley
Director
NUVL ·
Nuvalent, Inc.
On June 9, 2025, Emily Conley, a member of the board of directors (the “Board”) of Nuvalent, Inc. (the “Company”), notified the Company of her decision to resign from the Board and from all committees of the Board on which she serves, effective as of the date and time of the Company’s 2025 annual meeting of stockholders.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event other_material